Quantcast
Home > Quotes > BLUE
BLUE

bluebird bio, Inc. Common Stock (BLUE) Quote & Summary Data

$103.39
*  
1.48
1.45%
Get BLUE Alerts
*Delayed - data as of Dec. 14, 2018  -  Find a broker to begin trading BLUE now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
185
Today's High / Low
$ 103.48 / $ 100.50
Share Volume
738,444
50 Day Avg. Daily Volume
844,727
Previous Close
$ 101.91
52 Week High / Low
$ 236.1671 / $ 99.15
Market Cap
5,654,855,153
P/E Ratio
NE
Forward P/E (1y)
NE
Earnings Per Share (EPS)
$ -10.47
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
1.79

Intraday Chart

Shares Traded

Share Volume:
738,444
50 Day Avg. Daily Volume:
844,727

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -10.47

Trading Range

The current last sale of $103.39 is 4.28% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 103.48 $ 236.1671
 Low: $ 100.50 $ 99.15

Company Description (as filed with the SEC)

We are a clinical-stage biotechnology company committed to developing potentially transformative gene therapies for severe genetic diseases and cancer. With our lentiviral-based gene therapy and gene editing capabilities, we have built an integrated product platform with broad therapeutic potential in a variety of indications. We believe that gene therapy for severe genetic diseases has the potential to change the way these patients are treated by correcting the underlying genetic defect that is the cause of their disease, rather than offering treatments that only address their symptoms. Our clinical programs in severe genetic diseases include our LentiGlobin® product candidate as a treatment for transfusion-dependent ?-thalassemia, or TDT, and severe sickle cell disease, or severe SCD, and our Lenti-D(TM) product candidate as a treatment for cerebral adrenoleukodystrophy, or CALD, a rare hereditary neurological disorder.  ... More ...  


Risk Grade

Where does BLUE fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 100.79
Open Date:
Dec. 14, 2018
Close Price:
$ 103.39
Close Date:
Dec. 14, 2018

Consensus Recommendation

Analyst Info